The overall objective of the proposed Program Project Grant is to define factors and elucidate mechanisms involved in the interindividual variability in response following drug administration. The basic and clinical knowledge obtained from this research will provide a basis for the rational and safe use of drugs. The goals will be achieved by a group of investigators including clinical pharmacologists working in close collaboration with biochemical pharmacologists, as well as analytical and organic chemists. The population distribution, mode of inheritance and the pharmacological/toxicological consequences of genetic variability in drug elimination, especially that of a discontinuous nature, is of major interest, In particular, the deficient metabolism of the anticonvulsant, mephenytoin and a new antiarrhythmic agent, encainide, and the impaired elimination of the hypoglycemic tolbutamide will be studied. The involvement of a genetic factor in the development of arylamine-induced bladder cancer will also be investigated. The role of active and reactive metabolites in the efficacy and toxicity of antiarrhythmic agents will be investigated. Animal and clinical studies will be used to define the relative contributions of parent and metabolites to the overall pharmacological effects of encainide and quinidine. In addition, the involvement of a reactive metabolite(s) in the lupus-like syndrome resulting from procainamide therapy will be investigated. The effects of inhalation anesthesia on the distribution and metabolism of drugs will be studied in animal models. Specific questions that will be addressed include differences between anesthetics, such as halothane, enflurane, isoflurane and nitrous oxide, and the differential sensitivity of the disposition of various types of drugs to such agents. The contribution of alpha2 adrenoreceptors to the regulation of autonomic function in man will be systematically investigated, using yohimbine as a tool. the drug's clinical pharmacology will be defined in both normal subjects and patients with autonomic dysfunctions, and a model for a clinically evaluating this receptor sub-type will be developed. It is also planned to investigate the factors regulating beta adrenoreceptor affinity in man and to define the abnormalities produced by hypertension and thyrotoxicosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
5P01GM031304-04
Application #
3096153
Study Section
Pharmacology-Toxicology Review Committee (PTR)
Project Start
1982-12-01
Project End
1987-11-30
Budget Start
1985-12-01
Budget End
1986-11-30
Support Year
4
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37203
Johnson, Daniel H; Gebretsadik, Tebeb; Shintani, Ayumi et al. (2013) Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose. Br J Clin Pharmacol 75:997-1006
Kohli, Utkarsh; Pandharipande, Pratik; Muszkat, Mordechai et al. (2012) CYP2A6 genetic variation and dexmedetomidine disposition. Eur J Clin Pharmacol 68:937-42
Kohli, Utkarsh; Hahn, Maureen K; English, Brett A et al. (2011) Genetic variation in the presynaptic norepinephrine transporter is associated with blood pressure responses to exercise in healthy humans. Pharmacogenet Genomics 21:171-8
Ho, Richard H; Leake, Brenda F; Kilkenny, Dawn M et al. (2010) Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenet Genomics 20:45-57
Kohli, Utkarsh; Muszkat, Mordechai; Sofowora, Gbenga G et al. (2010) Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception. Eur J Pain 14:154-9
Muszkat, Mordechai; Kurnik, Daniel; Sofowora, Gbenga G et al. (2010) Desensitization of vascular response in vivo: contribution of genetic variation in the [alpha]2B-adrenergic receptor subtype. J Hypertens 28:278-84
Muszkat, Mordechai; Bialer, Omer; Blotnick, Simcha et al. (2010) Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. Clin Ther 32:347-56
Li, Chun; Schwarz, Ute I; Ritchie, Marylyn D et al. (2009) Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 113:3925-30
Haas, David W; Gebretsadik, Tebeb; Mayo, Gail et al. (2009) Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis 199:872-80
Kurnik, Daniel; Li, Chun; Sofowora, Gbenga G et al. (2008) Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenet Genomics 18:895-902

Showing the most recent 10 out of 351 publications